Workup of Severe Asthma
Authors:
- 1 December 2021
- Vol. 160 (6) , 2019-2029
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Boehringer Ingelheim
- GlaxoSmithKline
- AstraZeneca
- Merck
- Novartis
- Teva Pharmaceutical Industries
- Bayer
- Chiesi Farmaceutici
This publication has 56 references indexed in Scilit:
- Severe asthma: Advances in current management and future therapyJournal of Allergy and Clinical Immunology, 2012
- Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trialThe Lancet, 2011
- The minimally important difference of the Asthma Control TestJournal of Allergy and Clinical Immunology, 2009
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Efficacy of Esomeprazole for Treatment of Poorly Controlled AsthmaNew England Journal of Medicine, 2009
- IL‐13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cellsClinical & Experimental Allergy, 2008
- Measurement of IL-13–Induced iNOS-Derived Gas Phase Nitric Oxide in Human Bronchial Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004
- Occupational Respiratory DiseasesNew England Journal of Medicine, 2000